Shares of iCAD Inc (NASDAQ:ICAD) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.60 and traded as high as $7.67. iCAD shares last traded at $7.64, with a volume of 8,311 shares trading hands.
Separately, ValuEngine downgraded iCAD from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.
The firm has a market cap of $145.39 million, a price-to-earnings ratio of -19.79 and a beta of 1.18. The stock has a 50 day moving average of $7.10 and a 200 day moving average of $6.60. The company has a quick ratio of 1.62, a current ratio of 1.76 and a debt-to-equity ratio of 2.00.
iCAD (NASDAQ:ICAD) last posted its quarterly earnings results on Wednesday, October 30th. The technology company reported ($0.10) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.10). The business had revenue of $7.86 million during the quarter, compared to the consensus estimate of $7.43 million. iCAD had a negative return on equity of 76.99% and a negative net margin of 46.85%. As a group, analysts predict that iCAD Inc will post -0.58 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of ICAD. Vanguard Group Inc. grew its holdings in shares of iCAD by 105.8% during the second quarter. Vanguard Group Inc. now owns 800,870 shares of the technology company’s stock worth $5,102,000 after purchasing an additional 411,648 shares during the last quarter. River & Mercantile Asset Management LLP acquired a new position in iCAD in the second quarter valued at approximately $1,020,000. White Pine Capital LLC acquired a new position in iCAD in the second quarter valued at approximately $555,000. Granite Investment Partners LLC acquired a new position in iCAD in the second quarter valued at approximately $451,000. Finally, Acadian Asset Management LLC lifted its stake in iCAD by 118.5% in the second quarter. Acadian Asset Management LLC now owns 92,180 shares of the technology company’s stock valued at $588,000 after buying an additional 50,001 shares during the period. 25.39% of the stock is owned by hedge funds and other institutional investors.
iCAD Company Profile (NASDAQ:ICAD)
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.